Allspring Global Investments Holdings LLC Has $464,000 Stake in GSK PLC Sponsored ADR (NYSE:GSK)

Allspring Global Investments Holdings LLC lifted its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 11.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,413 shares of the pharmaceutical company’s stock after acquiring an additional 1,248 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in GSK were worth $464,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. First PREMIER Bank lifted its holdings in GSK by 6.5% during the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company’s stock worth $181,000 after buying an additional 286 shares during the period. Northwest Bank & Trust Co lifted its holdings in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock worth $765,000 after buying an additional 289 shares during the period. Rhumbline Advisers lifted its holdings in GSK by 2.1% during the 1st quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock worth $713,000 after buying an additional 386 shares during the period. Rothschild Investment LLC lifted its holdings in GSK by 3.3% during the 1st quarter. Rothschild Investment LLC now owns 12,272 shares of the pharmaceutical company’s stock worth $475,000 after buying an additional 396 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in GSK by 23.0% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 2,233 shares of the pharmaceutical company’s stock worth $75,000 after buying an additional 417 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on GSK. BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price on the stock. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Berenberg Bank reissued a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $37.38.

GSK Stock Performance

GSK stock opened at $39.56 on Friday. The stock has a 50-day moving average price of $38.99 and a 200-day moving average price of $37.23. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The firm has a market cap of $80.98 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.57 and a beta of 0.50.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period in the previous year, the company posted $0.43 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were given a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a yield of 4.26%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, May 16th. GSK’s payout ratio is presently 88.14%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.